This regulatory effect was highlighted in studies by Ping Du et al. [116], where blocking the MALAT1/miR-224-5p/NLRP3 pathway was found to reduce hippocampal inflammation in T2DM, particularly regarding the activation of microglial NLRP3 inflammasomes in neuroinflammation and neurodegeneration. This evidence concerns the gene MALAT1 and type 2 diabetes mellitus.